Axial spondyloarthritis is a chronic inflammatory disease that primarily attacks the spine and sacroiliac joints, the joints connecting the lower spine to the pelvis. It typically begins in young adults, often before age 30, with persistent back pain and morning stiffness that improve with movement but not rest. The condition sits on a spectrum, ranging from an earlier stage with no visible damage on standard X-rays to the well-known end stage called ankylosing spondylitis, where new bone growth can eventually fuse vertebrae together. Despite affecting an estimated 0.5 to 1 percent of the general population, axial spondyloarthritis remains widely underrecognized, and the average person waits years after symptoms begin before receiving a correct diagnosis.
The Disease Spectrum
Rheumatologists now think of axial spondyloarthritis (axSpA) as one disease with two stages. In the earlier phase, called non-radiographic axial spondyloarthritis (nr-axSpA), inflammation is active in the sacroiliac joints and spine, but it hasn’t caused enough structural damage to show up on a conventional X-ray. Once X-ray changes become visible, the classification shifts to radiographic axSpA, which is essentially what was traditionally called ankylosing spondylitis (AS). A study comparing the two groups in a Mexican cohort found that patients with nr-axSpA had lower disease activity and functional impairment scores than those with established AS, and were less likely to be male or carry the HLA-B27 gene variant associated with the condition.1Scientific Reports. Differences between radiographic and non-radiographic axial spondyloarthritis patients in a Mexican cohort
The distinction matters because some people with nr-axSpA will progress to AS over time, while others will not. A review in RMD Open identified three key ways the groups tend to differ: the degree of limited mobility and physical function, the proportion of patients showing elevated inflammatory markers in blood tests, and the male-to-female ratio, which tilts heavily male in AS but is closer to even in nr-axSpA.2RMD Open. Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences? This near-equal sex ratio in nr-axSpA is one reason the disease was historically missed in women: doctors were trained to look for ankylosing spondylitis as a “young man’s disease,” and the criteria at the time required X-ray damage that women develop more slowly.
Why Diagnosis Takes So Long
The delay between first symptoms and a correct axSpA diagnosis is one of the most frustrating aspects of the condition. A systematic review and meta-analysis found that the average diagnostic delay has been reported across many countries, with factors like lower education levels, younger age at symptom onset, and the absence of extra-articular features consistently linked to longer waits.3PubMed. Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis A U.S. study of over 550 axSpA patients put the median delay at roughly four years, though some patients waited a decade or more. That study also found that people living in areas with higher social vulnerability had about twice the odds of experiencing longer delays.4PubMed Central. Factors Associated With Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
Several factors stack against early recognition. Back pain is extraordinarily common in the general population, and most of it is mechanical, so clinicians don’t always think to investigate inflammatory causes in a 20-something. Seeing more healthcare professionals before reaching a rheumatologist paradoxically extends the delay, as does being female or having symptoms that start at a very young age.5PubMed Central. Diagnostic delay in patients from the International Map of Axial Spondyloarthritis: geographic, sociodemographic and disease-related factors The irony with uveitis, a painful eye inflammation, is striking: although it’s one of the strongest clinical clues that someone has axSpA, having a history of uveitis before diagnosis was actually associated with longer diagnostic delay in both the international and U.S. datasets, possibly because eye doctors and rheumatologists don’t always communicate efficiently.6PubMed Central. Factors Associated With Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability
Imaging and How It Changes the Picture
MRI has transformed the ability to detect axSpA early. Unlike X-rays, which only show bone damage after it has already occurred, MRI can pick up active inflammation (bone marrow edema) in the sacroiliac joints while damage is still reversible. In a head-to-head comparison, MRI bone marrow edema was the most sensitive finding for nr-axSpA, identifying the condition in about 88 percent of patients. Low-dose CT, by contrast, caught structural changes in roughly 44 percent of the same group but had higher specificity, meaning it was better at ruling out the disease in people who didn’t have it.7PubMed. MRI compared with low-dose CT scanning in the diagnosis of axial spondyloarthritis In practice, most rheumatologists use MRI as the frontline imaging tool when they suspect axSpA but X-rays look normal, and then use CT or plain radiographs to track structural progression over time.
Current biomarkers, while helpful, aren’t perfect either. HLA-B27, C-reactive protein, and erythrocyte sedimentation rate all have at best moderate value for diagnosis and predicting outcomes. Researchers are exploring genomic approaches like polygenic risk scores, along with microbiome profiling and protein-based markers, to build more informative diagnostic panels.8PubMed. Biomarker development for axial spondyloarthritis For now, diagnosis remains a clinical judgment call that combines imaging, blood work, physical exam, and careful history-taking.
How Sex and Gender Shape the Disease
Men and women with axSpA can have strikingly different experiences. Male patients tend to accumulate more radiographic spinal damage and higher structural progression scores, which is one reason AS has historically been seen as a predominantly male disease. But women report higher disease activity scores, worse quality of life, and, critically, lower response rates to TNF inhibitors, one of the main drug classes used to treat the condition.9PubMed Central. Gender Differences in Axial Spondyloarthritis: Women Are Not So Lucky These sex-based differences appear to stem from a combination of immunological, hormonal, and genetic factors, including different allelic frequencies for certain genes and different circulating levels of inflammatory molecules like TNF, IL-6, and IL-17.
An Egyptian cohort study reinforced many of these patterns, showing that women were diagnosed later, presented more often with peripheral arthritis and enthesitis (inflammation at tendon or ligament insertion points) rather than classical low back pain, and had higher disease activity and enthesitis scores.10Egyptian Rheumatology and Rehabilitation. Gender differences in axial spondyloarthritis regarding clinical, radiological characteristics and response to treatment in an Egyptian Cohort Study The practical takeaway is that women with persistent pain in the heels, rib cage, or pelvis who also have morning stiffness deserve the same level of suspicion for axSpA as men with classic low back symptoms, even though many screening tools still lean on the traditional male presentation.
Beyond the Spine
Axial spondyloarthritis is not just a spinal disease. Inflammation can crop up in the eyes, skin, and gut, and these so-called extra-articular manifestations (EAMs) are common enough to be considered part of the disease itself. A review estimated that anterior uveitis occurs in roughly 25 to 30 percent of patients over their lifetime, psoriasis in about 10 to 25 percent, and inflammatory bowel disease in 5 to 10 percent, along with cardiovascular complications.11PubMed Central. Management and evaluation of extra-articular manifestations in spondyloarthritis These ranges vary by population; a Moroccan study of 400 axSpA patients found EAMs in about 30 percent, with IBD being the most frequent, followed by uveitis.12PubMed. The Burden of Extra-Articular Manifestations in Axial Spondyloarthritis: A Moroccan Single-Centre Study
EAMs are not merely inconvenient side features. Patients who develop them tend to have longer disease duration, higher disease activity, and worse physical function compared to those without.13PubMed. The Burden of Extra-Articular Manifestations in Axial Spondyloarthritis: A Moroccan Single-Centre Study A large registry analysis found that a history of psoriasis was significantly associated with both higher disease activity and greater functional impairment, and a history of IBD was similarly linked to higher disease activity.14Arthritis & Rheumatology. Is There an Impact of Uveitis, Psoriasis and Inflammatory Bowel Disease on Musculoskeletal Disease Activity and Function in Axial Spondyloarthritis? This means that managing axSpA well often requires coordination among rheumatologists, ophthalmologists, dermatologists, and gastroenterologists, and a patient who develops red, painful eyes or chronic diarrhea alongside back pain should mention all symptoms to every specialist involved.
The Gut Connection
The overlap between axSpA and gut inflammation goes deeper than coincidental IBD. Research has found that people with spondyloarthritis, including axSpA, tend to have reduced levels of certain beneficial gut bacteria, particularly species in the Firmicutes group like Faecalibacterium prausnitzii and Clostridium leptum, bacteria that play important anti-inflammatory roles. These same bacterial shifts show up in IBD, psoriatic arthritis, and juvenile spondyloarthritis, suggesting a shared biological link.15PubMed Central. The intestinal microbiome in spondyloarthritis
An observational cohort study added a structural dimension to the gut-spine relationship. Using fecal calprotectin, a marker of intestinal inflammation, researchers found that axSpA patients with elevated levels had significantly more spinal damage. Those with elevated calprotectin had about twice the odds of having structural damage scores above the group’s median, and the association was even stronger when looking only at patients with established AS.16PubMed Central. Gut inflammation is associated with structural spinal damage in axial spondyloarthritis – results from the observational SPARTAKUS cohort Whether gut inflammation directly drives spinal damage or both are downstream of the same immune pathway is an active area of research. The IL-23/IL-17 immune axis, which occupies a central position in axSpA pathogenesis, is also a major player in gut immune regulation, which may explain why inflammation in the two sites tends to travel together.17PubMed Central. Targeting the interleukin-23/17 axis in axial spondyloarthritis
How Bone Gets Remodeled
One of the most distinctive features of axSpA, especially in its later stages, is paradoxical bone remodeling. The disease involves both bone erosion from inflammation and excessive new bone formation that can lead to bony bridges (syndesmophytes) between vertebrae and eventually spinal fusion. The signaling pathways involved in this abnormal new bone growth include bone morphogenetic proteins and the Wnt pathway, both of which have been found to be deregulated in axSpA, though the trigger for their uncontrolled stimulation remains unclear.18PubMed. Molecular mechanisms of bone formation in spondyloarthritis This dual process is part of why treatment can be complicated: suppressing inflammation is necessary but may not fully prevent structural progression, particularly in patients who already have syndesmophytes forming.
Treatment Options
First-line treatment for axSpA starts with regular exercise and nonsteroidal anti-inflammatory drugs (NSAIDs) like naproxen or celecoxib. Unlike in rheumatoid arthritis, conventional disease-modifying drugs such as methotrexate or sulfasalazine do not work for spinal symptoms in axSpA. When NSAIDs aren’t enough, biologic drugs are the next step. TNF inhibitors (like adalimumab, etanercept, and infliximab) were the first biologics approved for axSpA and remain widely used. IL-17 inhibitors (such as secukinumab and ixekizumab) offer a second biologic class. A nationwide cohort study found no significant difference in overall drug retention between IL-17 inhibitors and TNF inhibitors when used after a first TNF inhibitor failed, though among patients whose initial TNF inhibitor failed due to lack of effect (primary failure), IL-17 inhibitors were associated with significantly longer drug survival.19PubMed Central. Persistence of IL-17 and TNF inhibitors following initial TNF inhibitor use in axial spondyloarthritis
For patients who don’t respond adequately to either TNF or IL-17 inhibitors, Janus kinase (JAK) inhibitors have emerged as a newer option. Tofacitinib and upadacitinib are now approved for axSpA, with upadacitinib being the first in this class to show benefit in nr-axSpA as well, meaning it works across the full disease spectrum. Both drugs improved pain, disease activity, physical function, and quality of life.20PubMed Central. JAK Inhibitors for the Treatment of Axial Spondyloarthritis21Indian Journal of Dermatology, Venereology and Leprology. Efficacy and safety of Janus kinase inhibitors in axial spondyloarthritis A meta-analysis comparing JAK inhibitors to secukinumab (an IL-17 inhibitor) in patients with active AS found no significant difference in treatment response rates between them, and safety profiles were comparable across all groups.22PubMed Central. Comparative Efficacy and Safety of Janus Kinase Inhibitors and Secukinumab in Patients with Active Ankylosing Spondylitis: A Systematic Review and Meta-Analysis
Exercise as Treatment, Not Just Advice
Exercise in axSpA is not a polite afterthought appended to a prescription. It’s one of the few interventions with evidence supporting improvements across multiple disease outcomes. A systematic review found moderate evidence that exercise improves physical function, disease activity, and chest expansion (an important measure because rib cage involvement can restrict breathing), along with lower-level evidence for improvements in pain, stiffness, spinal mobility, and heart-lung fitness. The review also found that supervised group exercise produces better results than unsupervised home exercise.23PubMed. Exercise therapy for spondyloarthritis: a systematic review
A more recent study examined the effects of daily physical therapy over two weeks in axSpA patients and found clinically meaningful improvements in both function and spinal mobility, including electronic measurements of range of motion and speed of movement.24PubMed Central. Impact of daily physical therapy over 2 weeks on spinal mobility including objective electronic measurements and function in patients with axial spondyloarthritis High-intensity exercise has also been shown to improve fatigue, sleep quality, and mood in axSpA, outcomes that medications alone don’t always address well.25Physical Therapy. High-Intensity Exercise Improves Fatigue, Sleep, and Mood in Patients With Axial Spondyloarthritis: Secondary Analysis of a Randomized Controlled Trial The combination of a drug that dampens inflammation and a regular exercise program that preserves mobility and cardiovascular fitness is generally considered the ideal approach.
When Symptoms Start in Childhood
AxSpA can begin before age 16, and when it does, the presentation tends to look quite different from the adult version. Children and adolescents with spondyloarthritis are more likely to present with peripheral arthritis, often in a knee or ankle, and enthesitis at the heel or around the kneecap, rather than the classic inflammatory back pain that adults describe. A Chinese cohort study comparing juvenile-onset and adult-onset nr-axSpA confirmed that peripheral arthritis was significantly more common in the younger group, while inflammatory back pain dominated the adult group.26PubMed Central. Comparison of clinical characteristics between adult-onset and juvenile-onset non-radiographic axial spondyloarthritis in Chinese patients: results from the COCAS cohort
This different starting pattern contributes to even longer diagnostic delays. A Turkish study found that patients with juvenile-onset AS waited an average of about nine years for a diagnosis compared to roughly five years for adult-onset patients. The juvenile-onset group also had more prevalent uveitis and peripheral involvement at onset.27The Journal of Rheumatology. Pattern of Disease Onset, Diagnostic Delay, and Clinical Features in Juvenile Onset and Adult Onset Ankylosing Spondylitis Because a teenager with a swollen knee and heel pain doesn’t match most physicians’ mental image of someone with a spinal disease, the connection to spondyloarthritis often goes unrecognized for years.
Pregnancy and Axial Spondyloarthritis
Women with axSpA who are planning a pregnancy face a specific challenge. Many are on TNF inhibitor therapy when they conceive, and the usual practice has been to discontinue these medications upon a positive pregnancy test. A prospective study of 61 axSpA pregnancies found that patients who stopped TNF inhibitors had a threefold increased risk of disease flare during the second trimester. Even after restarting treatment or adding corticosteroids in the majority of these patients, disease activity remained elevated throughout the rest of the pregnancy.28PubMed Central. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients Women who were not on a TNF inhibitor before pregnancy showed persistently high disease activity from the preconception period through postpartum, suggesting that undertreated axSpA does not naturally calm down during pregnancy the way rheumatoid arthritis sometimes does. Current guidelines are evolving, with growing support for continuing certain TNF inhibitors (particularly certolizumab, which has minimal placental transfer) through at least the second trimester under rheumatology and obstetric supervision.
Work, Fatigue, and Economic Burden
AxSpA strikes during peak working years, and its impact on employment and daily function can be substantial. Key drivers of work disability include higher disease activity, poorer physical function, pain, fatigue, and sleep disturbance.29PubMed Central. Work Disability in Axial Spondyloarthritis Fatigue is often reported by patients as equally debilitating as pain; it doesn’t simply track with how inflamed the joints are and can persist even when inflammatory markers are controlled. Sleep quality is frequently poor as well, partly from nighttime pain and stiffness that interrupt rest.
The economic cost extends beyond individual suffering. A study of axSpA patients in Singapore estimated the overall annual societal cost at roughly 75 million U.S. dollars, with direct medical costs (drug therapy, outpatient visits, hospitalizations) accounting for about 91 percent of the total and indirect costs (lost productivity, absenteeism) making up the remainder.30PubMed Central. The direct and indirect costs of axial spondyloarthritis (axSpA) in Singapore Biologic and targeted therapies are expensive, but untreated or poorly treated disease generates its own costs through disability payments, lost working hours, and reduced earning capacity over a lifetime.
An Ancient Disease With a Modern Identity
Axial spondyloarthritis is not a new condition, even if its modern classification system dates only to 2009. Evidence of the disease has been found in ancient Egyptian mummies, and the link between ankylosing spondylitis and the HLA-B27 gene was established in the 1970s, one of the first strong gene-disease associations identified in medicine.31PubMed Central. A brief human history of ankylosing spondylitis: A scoping review of pathogenesis, diagnosis, and treatment What has changed dramatically is the understanding that the disease encompasses a broader spectrum than the fused-spine picture of classical AS, and that catching it before structural damage occurs opens a window for treatments that can preserve mobility. With MRI, newer biologics, JAK inhibitors, and growing recognition that the disease is not confined to young men, outcomes for people with axSpA are better than they have ever been. The remaining gap is getting those tools applied early enough, and to everyone who needs them.